We are targeting the unique vulnerability of undetected disseminated tumor cells (DTCs) before they can cause deadly metastatic recurrence, the spread of cancer from primary tumors to secondary, distant sites.
This vulnerability of DTCs stems from their dependence on a unique phenotype that includes stress adaptation, survival & dormancy, which we have coined “Metastatic Endurance” (ME). ME enables DTCs to persist undetected at secondary sites like “ticking time-bombs” and eventually start to rapidly divide and form overt deadly tumors. We find drugs that disable ME.
This is a game-changing approach to addressing metastatic cancer recurrence, the cause of ~90% of cancer deaths.